suggest that menopause may play a role in the decrease of tumor size, other growth factors may contribute.
Spirometry in the Diagnosis of Small Airways Obstruction
To the Editor:
In the article titled "Small Airways Obstruction Syndrome" (July 1999), 1 Dr. Stȃnescu reported on four patients with the functional pattern of decreased vital capacity (VC) and FEV 1 , normal FEV 1 /VC ratio and total lung capacity, and increased residual volume (RV). In these patients, Dr. Stȃnescu alleges, the obstructive pattern would be overlooked on routine spirometry unless RV also was measured.
While a low VC or a low FEV 1 may result from either a restrictive or an obstructive defect, the FEV 1 /VC ratio should be the primary guide to distinguish between the two patterns. 2 Three of the four subjects in Dr. Stȃnescu's study have FEV 1 /VC ratios Ͻ 70%, which would, therefore, place them in the appropriate category of obstructive defect without the need for RV measurement. Additionally, the study did not provide other spirometric data such as on the midexpiratory phase of forced expiratory flow (FEF 25-75% ), which may also be useful in confirming the presence of airways obstruction in the presence of a borderline FEV 1 /VC ratio. 2 During a review of our laboratory data, we discovered this pattern in several subjects who had correctly had obstruction diagnosed based on the spirometric assessment alone, which showed a disproportionate decrease in FEF 25-75% and a normal FEV 1 /VC ratio (confirmed, of course, by the presence of a high RV and RV/TLC ratio). To the Editor:
Ravichandran
I thank Drs. Theerthakarai and Khan for their interest in my article (July 1999). 1 Alluding to the American Thoracic Society (ATS) statement, 2 the authors write that the FEV 1 /vital capacity (VC) ratio should be the primary guide to distinguish between a restrictive and an obstructive defect. Of course, the authors are correct. But the problem is how to define the defect, when FEV 1 /VC ratio is within normal limits, and both FEV 1 and VC are decreased, ie, the syndrome we have described. 1 Drs. Theerthakarai and Khan assert that three of our four patients have FEV 1 /VC ratios Ͻ70%, which would therefore place them in the appropriate category of obstructive defect without the need for residual volume (RV) measurement. I was surprised by this affirmation. According to the ATS statement 2 they quote, "defining a fixed FEV 1 /VC [vital capacity] ratio as a lower limit of normal [my emphasis] is not recommended in adults because FEV 1 /VC is indirectly related to age and height." All our four subjects had percentage of predicted FEV 1 /VC ratios within normal limits, as shown in Table 1 . We also computed in our subjects expected values for the FEV 1 /VC ratio using two well-known American formulas. 3, 4 According to subjects' ages and heights, the FEV 1 /VC ratios of our subjects were also within expected limits. Therefore, the FEV 1 /VC ratio of the patients we presented did not place them in the category of obstructive defect!
The authors also write that they have "discovered this pattern in several subjects who were correctly diagnosed as obstructive, based on the spirometric assessment alone, showing a disproportionate decrease in FEF 25-75% [forced expiratory flow after 25 to 75% of VC has been expelled] and normal FEV 1 /VC ratio (confirmed, of course, by a high RV and RV/TLC [total lung capacity] ratio)". One might ask why the authors needed another measurement (FEF 25-75% ) when the defect was correctly diagnosed by a high RV and RV/TLC and normal FEV 1 /VC?
The ATS guidelines 2 suggest that, indeed, in the presence of a borderline FEV 1 /VC, maximal expiratory flow rates may help confirm the presence of airway obstruction. But FEV 1 /VC ratios in our subjects were not borderline. They were within normal limits. Furthermore, the guidelines 2 emphasize that "when FEV 1 /VC ratio is within the expected range, abnormalities in flow occurring late in the maximal expiratory flow-volume curve, should not be graded as to severity, and, if mentioned, interpretations of their clinical significance should be guarded." A 56-year-old man was admitted to Hiroshima University Hospital in 1987 because of radiographic evidence of pulmonary abnormalities, fever, and anorexia. A radiograph of the chest showed bilateral thickening of the pleura in the middle field. A CT scan of the chest disclosed remarkable thickening of the pleura and a tumorous lesion, 2 ϫ 3.5 cm in diameter, with a low density area in the right lung (Fig 1) . Because the etiology was unknown except in the lungs, an exploratory thoracotomy was performed. A microscopic examination of the resected specimen disclosed that the tumor was composed of a proliferation of fibroblasts and an infiltration of plasma cells, macrophages, and lymphocytes accompanied by a local accumulation of hyaline collagen layers (Fig 2) . Because a low-grade fever and increased levels of C-reactive protein remained after the operation, 20 mg/d prednisolone was administered. After 2 weeks of corticosteroid treatment, the symptoms improved, and the dose of prednisolone was gradually tapered. No recurrence was observed after 10 years of follow-up. Inflammatory pseudotumors are rare diseases that generally occurs in the lung. To our knowledge, there is only one report describing an inflammatory pseudotumor presenting pleural thickening that showed spontaneous regression. 1 Ishida et al 2 reported that, intraoperatively, the parietal pleura was involved in three of seven patients with inflammatory pseudotumors. In our patient, although the histologic examination of the resected pleura revealed remarkable fibrosis without evidence of inflammatory pseudotumor involvement, adjacency between the tumor and the pleural thickening suggested a relationship of these lesions. After complete resection of the tumor, the symptoms remained, suggesting an active lesion in the remaining thickening pleura.
The diagnosis of inflammatory pseudotumor is not commonly made before resection, and complete resection leads to an excellent prognosis. 3 Unresected or recurred cases in patients were reportedly treated with corticosteroids, which resulted in a decrease in size or complete regression. 4, 5 Before corticosteroid treatment, our patient was treated with nonsteroidal anti-inflammatory drugs, which were not effective. These observations suggest that corticosteroids may be an option in treating inflammatory pseudotumors. Figure 1 . A CT scan of the chest disclosed remarkable thickening of the pleura and a tumorous lesion, 2 ϫ 3.5 cm in diameter, with a low density area in the right lung. Thickening of the pleura was also observed in the left lung. Figure 2 . A microscopic examination of the resected specimen disclosed that the tumor was composed of a proliferation of fibroblasts and an infiltration of plasma cells, macrophages, and lymphocytes accompanied by a local accumulation of hyaline collagen layers (hematoxylin-eosin, original ϫ 100).
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